Effects of awareness of breast cancer overdiagnosis among women with screen-detected or incidentally found breast cancer: a qualitative interview study

Kristen Pickles 1,1, Jolyn Hersch 1,1 Brooke Nickel 1,1 Jayant S Vaidya 1,2 Kirsten McCaffery 1,1 Alexandra Barratt 1

ABSTRACT

Objectives To explore experiences of women who identified themselves as having a possible breast cancer overdiagnosis.

Design Qualitative interview study using key components of a grounded theory analysis.

Setting International interviews with women diagnosed with breast cancer and aware of the concept of overdiagnosis.

Participants Twelve women aged 48–77 years from the UK (6), USA (4), Canada (1) and Australia (1) who had breast cancer (ductal carcinoma in situ n=9, (invasive) breast cancer n=3) diagnosed between 2004 and 2019, and who were aware of the possibility of overdiagnosis. Participants were recruited via online blogs and professional clinical networks.

Results Most women (10/12) became aware of overdiagnosis after their own diagnosis. All were concerned about the possibility of overdiagnosis or overtreatment or both. Finding out about overdiagnosis/ overtreatment had negative psychosocial impacts on women’s sense of self, quality of interactions with medical professionals, and for some, had triggered deep remorse about past decisions and actions. Many were uncomfortable with being treated as a cancer patient when they did not feel ‘diseased’. For most, the recommended treatments seemed excessive compared with the diagnosis given. Most found that their initial clinical teams were not forthcoming about the possibility of overdiagnosis and overtreatment, and many found it difficult to deal with their set management protocols.

Conclusion The experiences of this small and unusual group of women provide rare insight into the profound negative impact of finding out about overdiagnosis after breast cancer diagnosis. Previous studies have found that women valued information about overdiagnosis before screening and this knowledge did not reduce subsequent screening uptake. Policymakers and clinicians should recognise the diversity of women’s perspectives and ensure that women are adequately informed of the possibility of overdiagnosis before screening.

Overdiagnosis is the diagnosis or detection of a cancer that, without screening, never would have led to clinical symptoms or death during a person’s lifetime.1 Estimates of overdiagnosis from observational and modelling studies vary from 10% to 30%, depending on the study methods2–4 but the Independent UK Panel concluded that for every 10 000 women invited to screening from age 50 for 20 years, about 681 cancers will be found of which 129 will represent overdiagnosis, and 43 deaths from breast cancer will be prevented. They estimated that in the UK, about 3000 women are overdiagnosed with breast cancer every year, and about 1000 deaths from breast cancer are prevented. The panel recommended that this information should be clearly communicated to women.5

Overdiagnosis is a difficult concept to communicate and to understand, particularly because women with overdiagnosed cancers cannot be individually identified. In the UK, information about overdiagnosis has been included in a leaflet sent out with women’s invitations to be screened since 2013 but concerns remain that the risk of overdiagnosis is not adequately reflected in the information provided to the public by the National Health Service (NHS).5 In the USA, Canada
and Australia, women are generally invited to screening without receiving clear information on overdiagnosis. Evidence suggests that most women are still not aware of the possibility of overdiagnosis, with the benefits of screening largely dominating public opinion. This may change with time as community knowledge grows, and as more women participate in treatment de-escalation trials for low-risk breast cancers.

Being aware of overdiagnosis, however, may increase distress and uncertainty for those women diagnosed with asymptomatic breast cancer, compared with women who are not aware of this possibility. This is because ‘neither the woman nor her doctor can know whether this particular cancer would have become apparent without screening and could possibly lead to death or is one that would have remained undetected for the rest of the woman’s life’. As such women who know about overdiagnosis may wonder whether the cancer found by screening truly requires treatment or if they are enduring treatment and its related side effects for no benefit. Two recent studies—one in patient with thyroid cancer and one in men with prostate cancer—found that patients diagnosed with cancer who chose not to undergo recommended treatment because they believed they were overdiagnosed felt overwhelmingly isolated and anxious, with some participants withdrawing themselves from the healthcare system altogether. We are not aware of any comparable studies exploring this issue in patients with breast cancer. Therefore, in the current study we aimed to understand women’s perceptions and experiences of living with (what they perceived to be) a possibly overdiagnosed screen-detected breast cancer. This study used in-depth interviews to explore how women experience living with a perceived possible overdiagnosis or overtreatment of breast cancer. Throughout this paper, the term ‘breast cancer’ includes both ductal carcinoma in situ (DCIS) and invasive breast cancer.

**METHODS**

**Design**

This study used qualitative interviews to explore the experiences of women diagnosed with screen-detected breast cancer, who knew of the concept of overdiagnosis and overtreatment and had applied this knowledge to their own situation. They were aware that it is virtually impossible for any individual to know for sure whether their particular cancer was overdiagnosed.

**Identification of participants and recruitment**

Women were recruited to the study through advertisements on blogs where overdiagnosis is discussed (‘DCIS411’: http://DCIS411.com and ‘Even Stars Explode’: https://evensparsexplode.wordpress.com/) (n=6), patients who had contacted AB via her publications on the topic of overdiagnosis of breast cancer (n=4), and through professional networks of the investigators (n=2). This approach was required to enable participation of women who may have been eligible without risking distress to women who were unaware of breast cancer overdiagnosis. Women were eligible if they had been diagnosed with screen-detected breast cancer (defined as a cancer detected in an asymptomatic woman) at least 6 months previously, were already aware of the idea of overdiagnosis or overdiagnosis in relation to screen-detected breast cancer, were 40 years of age or older at the time of diagnosis and were fluent in English. Women who had been diagnosed with breast cancer following symptomatic presentation, or who had advanced cancer at diagnosis, or were at high risk of cancer, for example because of a strong family history of breast cancer were not eligible. Participant’s understanding of overdiagnosis was checked before entry to the study to confirm prior knowledge. All participants provided informed consent to be interviewed.

Participants were recruited from four English speaking countries: Australia, Canada, USA and the UK. Such sampling from different countries enabled the researchers to understand how variations in breast screening policy and practice may affect women’s experiences and responses to their knowledge about overdiagnosis. For example, information about overdiagnosis is included with breast screening invitations in the UK but not in other countries, and government-funded population-based universal mammographic screening programmes exist in the UK but not in the USA.

**Interview procedures and content**

The women received an information sheet about the study and completed a short online survey prior to the interview. They reported demographic data, details about their diagnosis and treatment (table 1) and completed an eligibility check including defining overdiagnosis and overtreatment in their own words (online supplemental file 1).

Semistructured in-depth interviews were conducted by one researcher (KP) trained in qualitative research methods, from 13 December 2019 to 8 December 2020. The interviews occurred remotely by Zoom. This enabled us to easily include women from different countries, despite the ongoing COVID-19 global pandemic.

An interview topic guide was developed by the research team which included a practising breast cancer clinician and our consumer advisory panel (see online supplemental file 2). It was piloted with 7 people for whom making decisions about participating in mammography screening was relevant (4 researchers, 1 breast physician and 2 consumers), and refined prior to commencement of the interviews. Participants were asked to share their experiences related to their diagnosis and decision-making process around management options. They were also asked to give suggestions for other women considering breast screening in the future (online supplemental file 3).

We planned to interview as many women as possible who met the inclusion criteria during the study period as we envisaged that it may be challenging to find women
who were aware of overdiagnosis and overtreatment and willing to discuss their experience. One participant requested and received her transcript for review to ensure that she was not recognisable. All clinical data were self-reported.

The interviewer

The interviewer (KP) has a doctoral degree in public health and was working as a postdoctoral research fellow at the time of the interviews. KP has undertaken formal training in qualitative research methods. She had no immediate personal or professional experience with breast cancer or breast screening and no strong beliefs about the topic of the interviews.

Data analysis

Audio recordings were transcribed verbatim by a professional transcribing service. Each in-depth interview was

---

**Table 1** Characteristics of the study participants (n=12)

| Participant ID and year of diagnosis | Diagnosis          | Sought a second opinion (or more) | Management received*                                                                                       | When (and how) did you become aware of the concept of overdiagnosis? |
|-------------------------------------|--------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| P1 2015                             | DCIS               | Yes                              | Lumpectomy Endocrine (hormone) therapy Currently on tamoxifen                                            | Unsure about timing in relation to diagnosis (personal research, media, the internet) |
| P2 2016                             | DCIS               | No                               | Lumpectomy Physiotherapy for lymphatic cording Gene profile test                                         | After receiving treatment (personal research, the internet)         |
| P3 2019                             | DCIS               | Yes                              | Only diet and lifestyle changes                                                                          | After diagnosis (personal research)                                 |
| P4 2018/2019                        | DCIS               | Yes                              | Lumpectomy                                                                                               | After diagnosis (medical professional, personal research, the internet) |
| P5 2013                             | Breast cancer      | Yes                              | Mastectomy Endocrine (hormone) therapy                                                                   | After diagnosis (personal research, the internet)                  |
| P6 2010                             | DCIS               | Yes                              | Lumpectomy Gene profile test                                                                            | After diagnosis (personal research, the internet)                  |
| P7 2019                             | DCIS               | Yes                              | Active monitoring (personal choice)                                                                     | After diagnosis (personal research, media, family/friend/colleague, the internet) |
| P8 2016                             | Breast cancer      | Yes                              | Lumpectomy Radiotherapy (TARGIT-IORT)† Endocrine (hormone) therapy Gene profile test Chemotherapy Currently on tamoxifen | After diagnosis (medical professional, personal research, conference lecture) |
| P9 2012                             | Breast cancer      | Yes                              | Lumpectomy Radiotherapy (TARGIT-IORT)†                                                                   | Before screening (personal research, media, family/friend/colleague) |
| P10 2019                            | DCIS               | Yes                              | Lumpectomy                                                                                               | After diagnosis (breast, ovarian cancer education centre)          |
| P11 2004                            | Initially DCIS; invasive cancer found after initial lumpectomy | Yes                              | Lumpectomy Mastectomy                                                                                   | After receiving treatment (personal research)                      |
| P12 2013                            | DCIS; Invasive cancer after 3 years of no treatment | Yes                              | Active monitoring for 3 years. Then mastectomy. Then radiation and chemotherapy (to treat metastatic disease)‡ | After diagnosis (personal research, family/friends, internet, medical journals) |

*Self-reported. Gene profile test (eg, MammaPrint, Oncotype DX).
†TARGIT-IORT—targeted intraoperative radiotherapy during lumpectomy (no further postoperative radiotherapy).
‡Participant deceased.
DCIS, ductal carcinoma in situ.
analysed using key components of a grounded theory analysis, namely, an iterative thematic approach and constant comparative method. The data were collected and analysed concurrently. KP used the ‘comments’ function in Microsoft Word to make detailed notes throughout each transcript and identified points of interest to explore in future interviews.

Two researchers (KP and AB) read the first four transcripts to familiarise themselves with the data. This enabled KP, who does not have medical qualifications, to discuss the transcripts with AB who is a registered medical practitioner and epidemiologist, to ensure understanding of the women’s diagnoses and treatment descriptions and concepts of overdiagnosis and overtreatment for thematic analysis. Following a second reading, initial codes were developed by KP based on transcripts and notes (eg, ‘conflicting identities’, ‘incomplete understanding’) and discussed with a third researcher, JH, who read two transcripts and generated independent codes which were cross-checked with KP’s initial codes. These were then grouped into higher order organising themes. JH read an additional two transcripts and reviewed the preliminary themes to ensure accuracy of interpretation and added further interpretation and insights. The analysis constantly moved from specific codes and themes to the more general, with the aim of generating a comprehensive explanation of our findings across participants and the settings in which we conducted the study.

JSV, a surgeon and oncologist specialising in breast cancer, also read all transcripts to confirm that the analysis adequately conveyed correct and appropriate interpretation of clinical data. Discussion with the broader research team occurred regularly throughout the data analysis, interpretation and manuscript drafting process. Quotes that best illustrated the developing themes were extracted into tables alongside the themes; a selection of these quotes is included in the Results section. Four case studies are presented in online supplemental file 4, which were selected to represent a range of diagnoses, decision making processes, uncertainty about decisions made and responses from others regarding their preferred pathway. The women described diverse personal experiences relating to their diagnosis and decision-making processes, but there were also many commonalities in their stories particularly around identity, interactions with medical professionals, uncertainty about decisions made and responses from others regarding their preferred pathway. The stories of four participants (using pseudonyms) are summarised as case studies (online supplemental file 4).

Patient and public involvement

The study was initiated by AB in response to a patient’s personal experience of screen-detected breast cancer in 2012 and expressed concern about the possibility of overdiagnosis. This patient (from the UK) and two other women (one from the UK and one from the USA) with lived experience of screen-detected breast cancer were invited to join our study as consumer advisors from the inception of the study. All accepted and two also met the eligibility criteria and were interviewed as research participants. Our consumer advisors reviewed all study materials, assisted recruitment by hosting a study advertisement on their blogs and reviewed the draft manuscript. It is notable that all participants were given the opportunity to read and comment on the manuscript and their case study (if relevant) prior to publication, resulting in two minor amendments.

RESULTS

Participant characteristics

Twenty-two women expressed interest in participating in an interview; of these, 10 did not complete an interview: 6 were deemed ineligible because they had a strong family history of breast cancer (n=1) or their cancer was not screen-detected (n=5). We were not able to make follow-up contact with 3 women who expressed interest and 1 potential participant was unavailable to interview during study recruitment phase.

Twelve women were interviewed. The interviews ranged in duration from 50 to 123 min (mean 73 min).

Table 1 reports demographic and some clinical characteristics of the participants. Participants were located in four countries where breast screening is well established: UK (6), USA (4), Canada (1) and Australia (1). Most had a university degree (11/12), and they ranged in age from 48 to 77 years. Age at diagnosis was between 44 and 74 years (mean age 58 years), and their diagnoses occurred between 2004 and 2019. Eleven out of 12 women were diagnosed as a result of participating in mammography screening, and one participant was diagnosed with DCIS as an incidental finding on routine histopathological examination of breast tissue following breast reduction surgery. The primary diagnosis was DCIS in 9 of the 12 women and (invasive) breast cancer in 3 women. They had undergone a range of treatments (table 1); two women did not have any form of surgery. Almost all of the women interviewed had found out about breast cancer overdiagnosis as a result of personal research following their diagnosis and two women found out about it after they had received treatment.

Overview of findings

The women described diverse personal experiences relating to their diagnosis and decision-making processes, but there were also many commonalities in their stories particularly around identity, interactions with medical professionals, uncertainty about decisions made and responses from others regarding their preferred pathway. The stories of four participants (using pseudonyms) are summarised as case studies (online supplemental file 4).

Five main themes were identified across the interviews: (1) Discovering overdiagnosis; (2) Am I a cancer patient or not?; (3) Resisting overtreatment; (4) Living with the unknown and (5) Downstream effects on quality of life. All participants explained how they felt the ‘standard’ approach to treatment offered by their initial teams was inflexible and the pressure that they encountered to act in the recommended and expected way.

When the women were asked to reflect on their experience of learning about overdiagnosis and overtreatment and applying that knowledge to their personal situation, most of the participants recognised that something about
their personal circumstances enabled them to question their diagnosis and recommended management, and in some cases, to be able to avoid overtreatment. For example, a number of the women were employed in a profession that required them to ask questions, had relevant personal or professional networks and connections, private health insurance, or described themselves as being of a particular personality type (ie, not a shy person, ‘stroppy’, ‘more likely to challenge the opinion of a doctor than the vast majority of patients’ (Participant 8)) which enabled them to ask questions, find answers and ultimately change the way that they would have been treated.

**Discovering overdiagnosis**

Ten of the 12 women became aware of overdiagnosis after their diagnosis, including two who found out after they had received treatment. One was aware of it before screening mammogram, and one was unsure when she found out. Several participants elaborated, saying that while they had heard about the possibility that mammograms can detect non-lethal cancers, they developed a ‘much better understanding’ (Participant 1) when undertaking personal research following their diagnosis. Most of the women’s accounts indicated that they began their own research because they felt that they received different and often conflicting medical opinions and confusing information regarding their diagnosis. Many felt that the information that they obtained from their initial clinical teams was not sufficient for their personal needs and so this prompted them to proceed with further exploration and research independently. One participant described how,

> from the beginning… it just didn’t feel right, something felt off…it’s not right how they’re communicating about it…if I ask any questions it didn’t feel right…There was something that led me to continue…asking questions, researching (Participant 6).

Some were simply curious or uncertain about their diagnosis from the outset (many had not even heard of DCIS) and were motivated to further their knowledge before agreeing to the recommended treatment. One woman said,

> For a lot of women who get a diagnosis of breast cancer, to them it’s a no-brainer. Treat it, you know? Let’s get rid of it and then, then we’re ok. But… my… mental world wasn’t… composed in that way (Participant 5).

Several women named specific books, articles and clinicians that they encountered in their search for more information, that had led them to research overdiagnosis in-depth and said that these had been valuable sources of information on overdiagnosis. Finding out that there are different types of cancer was described as an ‘eye opener’ (Participant 12) and motivation to not have the recommended surgery immediately. For some, this process of getting informed became a full-time job, on which they and often their partners put in ‘a lot of work’ (Participant 1). Participant 3 initially undertook ‘typical googling’ and found the same things the doctor had told her, but

> It just didn’t feel right. Then, it just kind of snowballed…the more I read the more controversy I found…like finding the idea of overdiagnosis (Participant 3).

The women’s responses to finding out about overdiagnosis and overtreatment varied, on a spectrum from feeling ‘overjoyed’ to ‘tortured’. Finding out, for some—this was where they instantly identified, they felt seen, and it was a relief,

> It totally defined what I felt. It totally was validation and recognition…it was instant identification… I was overjoyed that this was being discussed in any way, because that’s what I identified with (Participant 6).

One participant felt ‘relieved’ because it confirmed that her preference to not have a mastectomy was not necessarily an overreaction. Women at this end of the spectrum reported that finding out eased some of the uncertainty they were experiencing, validated why they were feeling as they were, asking the questions they were, and verified that they were not the crazy angry irrational women that some had indicated that they were. Participant 7 felt that she had been ‘thrown a life raft’ when she discovered a blog where people were discussing overdiagnosis.

Yet a number of the women just felt shocked and sad on learning about overdiagnosis after their diagnosis and/or treatment, realising that they may have endured what they had perhaps unnecessarily:

> I thought, shock. Shock. What? You know? So you mean that I’ve been told I’ve got breast cancer and yet I might not have it?… from that point onwards (finding out about overdiagnosis) then really, I was actually tortured, I’d say, by the idea that I had been caught, unnecessarily by the screening program (Participant 5).

Several of the women in the cohort we studied expressed deep anger on finding out that they had not been informed about the possibility of overdiagnosis and overtreatment prior to breast screening. One participant only completely grasped the concept of overdiagnosis and what it possibly meant for her personal circumstances 3 years after her diagnosis and described finding out, and identifying with it, as one of the most painful experiences of her life.

> I had still thought that in my case because invasive cancer had been found that my life had been saved. It took a long time to come to understand that a lot of the papers written about overdiagnosis some were only talking about invasive cancer they didn’t even include DCIS in their estimates of overdiagnosis. Then
I realised that even some invasive cancer is known not to progress (Participant 11).

Two of the 6 UK participants had been invited to screening prior to information about overdiagnosis being included in screening leaflets that go with invitations to UK women for the NHS breast screen programme; for them the realisation of overdiagnosis was particularly painful, as they were months short of receiving updated patient information which cited overdiagnosis as a possible harm of mammography.

That was particularly painful…I just felt I’d been caught on the edge really of a change in policy and that actually the screening service…sent me a leaflet that they knew was not fit for purpose…and that made me extra angry (Participant 5)

Am I a cancer patient or not?

Most of the women’s reports suggested that they soon became aware—one they began asking questions and learning more about their diagnosis, overdiagnosis and overtreatment—that their circumstances and experience of breast cancer were unusual. Several interconnected issues of identity were apparent in the women’s accounts of their experience. First, several women described the challenges their diagnosis posed to their sense of self regarding how to classify themselves following their diagnosis.

…And then she told me all the appointments I would need to make. And you just go right into this fast forward…you’re a cancer patient now. And you’re treated just like a cancer patient (Participant 6).

Second, some of the women expressed feeling unsure regarding how to classify themselves following their diagnosis,

I had to come to grips with was I a cancer patient or wasn’t I a cancer patient? (Participant 2)

which in some cases was only exacerbated by disagreement among treating teams on whether their case was considered cancer or not (when the diagnosis was DCIS).

I was getting more and more confused…I had one professional telling me it wasn’t cancer…and another telling me, yes, it is cancer (Participant 4).

Many said that they had difficulty adjusting to being a ‘good compliant patient’ (Participant 2) and were dismayed at the expectation to fulfill this identity, especially those women who at the time were questioning whether the recommended treatment constituted overtreatment.

Lastly, several women who found out about overdiagnosis after diagnosis or treatment, identified entirely with the possibility that they may have been overdiagnosed, and not with being a cancer patient or survivor. These participants reported feeling conflicted over whether they were a cancer patient or not, and struggled against the cancer patient identity, yet were unable to escape or deny having been significantly impacted by a cancer diagnosis. This remained the case even over time, with two of the participants instead identifying themselves as victims of the medical system.

Let’s not call this disease. I’m not, I don’t feel diseased… I don’t identify with disease or illness or cancer…survivor, any of those terms. They’re just like…it’s almost insulting, especially when you feel like you’re a victim of overdiagnosis. Then you’re, that’s a double whammy. Because now you’re a victim in a sense from the medical system…this problem is a medically made problem (Participant 6).

Another talked about not being able to relate to the generic image of cancer,

It didn’t match my experience…the kind of metaphor was this thing invading your whole life and taking you over…I’m sure that’s how it is for many people who have cancer…I never really felt the cancer was the enemy…I felt the whole medical merry-go-round was, was my enemy (Participant 5).

They felt that they could not engage with breast cancer support groups because they did not identify as a cancer patient,

You just hear about everyone’s mastectomies and the radiation treatments and… I just felt I could never go back because I didn’t identify with that (Participant 6)

I didn’t want to do any of that because I didn’t want to identify as a cancer patient … their sympathetic nice caring responses to me would not have aligned to what I needed…I didn’t want to go to those kind of meetings and then…not say how I felt (Participant 5).

Resisting perceived overtreatment

All of the women described their disbelief in learning about the recommended treatment pathway after being told they had a screen-detected (or incidentally-detected, in one case) breast cancer. They perceived the scale of the surgery recommended as disproportionate to their understanding of the diagnosis they had been given which ‘might never progress’ (Participant 11), especially when they were not experiencing any symptoms.

In my head, I’m going, what is stage zero? Why would I need treatment for that? (Participant 2)

One participant, diagnosed with DCIS, commented that she did not at the time consider herself to have ‘real cancer’ so it was ‘absolutely ridiculous’ that a mastectomy was being recommended (Participant 6). Another said she had found it ‘completely ridiculous to have a mastectomy for something you don’t have yet. And you may
never have. I mean...that will not kill you (DCIS) (Participant 1).

They were telling me I needed surgery for something that might never progress...I was put into that dilemma...The surgery proposed at that time was a quadrantectomy, which seemed to me like a big deal, mutilating surgery for something that might never progress so I said no (Participant 11).

Two of the women (P2 and P12) believed that having biopsies or surgery can stimulate the spread of cancer.

Most participants had encountered criticism in response to their curiosity and requests for more information to enable an informed decision about their management plan. They described the 'uncomfortable' exchanges (Participant 5) that they felt took place when they asked their clinicians questions about their diagnosis or overdiagnosis or challenged the advised treatment pathways. They also described a rising sense that they were taking their life in their own hands (Participant 6), with doctors acting ‘totally uncomfortable with the fact that I was now choosing to do, in her words, nothing’ (Participant 3).

One participant—who had studied biochemistry—said she was asking informed and intelligent questions of her doctors and radiologist but felt she was not getting any answers, as ‘they didn’t like me asking’ (Participant 12).

I said to my husband, I don’t think I’m having that surgery. And my husband’s initial thing was like, I don’t know what you’re getting into your head. You can’t just read stuff on the internet and think that you’re better than the doctor. The doctors know best (Participant 3).

The women talked about the pressure that they encountered to act in the specified, recommended way, including from partners, friends and family members. Some women reported requests for a more conservative treatment approach were not readily accepted by medical practitioners: one woman described being told ‘you’re making a very bad decision’ when she opted not to have a mastectomy (Participant 8), another felt she was treated like she was doing something dangerous (Participant 3) or suicidal (Participant 10). As a consequence, some women sought a second opinion, and in some cases reported being pleased to find an alternative approach, some women sought a second opinion, and in some cases reported being pleased to find an alternative approach, with a doctor who they felt was more open to discussing different options and willing to consider evidence on overdiagnosis or more conservative care.

Our participants described situations where they felt they were laughed at, treated like ‘a mad woman’ (Participant 12), ‘negligent...foolhardy and arrogant’ (Participant 1). One participant reported being told she had ‘anger management issues’ by people on breast cancer internet forums, who felt that it was best ‘to just trust my surgeon, not Google’ (Participant 5).

At first everyone treated me like a difficult woman because I said I don’t want a mastectomy, I want monitoring please and let’s keep an eye on it and see if it develops or not because I was aware of overdiagnosis and didn’t want a mastectomy if it wasn’t absolutely necessary (Participant 12).

The clinician...was absolutely incensed that I had decided not to have a mastectomy...she says...what kind of nonsense have you been reading? What are you doing? (Participant 1)

Several participants encountered similar responses when they turned to online forums and breast cancer support groups after finding themselves unable to get the conversations that they wanted with medical professionals. However rather than finding support, they reported feeling misunderstood and isolated when they voiced their concerns about overdiagnosis and overtreatment.

It seemed like they were all doing the very aggressive treatments and...they were also kind of bullying me. And making me feel bad and saying, I wouldn’t leave it. That’s, you know, crazy. Like, I wouldn’t wait till... I want to live for my kids and ...all that kind of mentality. And I just thought, I’m looking for a support group and I’m not finding any support (Participant 6).

It was clear that most of the women had at some point felt lonely and isolated as a result of questioning their diagnosis and treatment, and in their efforts to inform other women about the possibility of overdiagnosis and overtreatment,

It’s something you can’t really talk about because so many women don’t understand. You’re saying something terrible and they get quite upset. It’s also quite isolating in that I can’t mention it to women of my age because they all think it (screening)’s a good thing to do. Far be it for me to rock the boat. I’ve received too many brickbats and insults. I was only trying to help (Participant 11).

Living with the unknown

It was apparent across the interviews that a number of the women were managing feelings of self-blame and regret many years after receiving their diagnosis and/or treatment because of their knowledge of overdiagnosis and overtreatment. Some of the participants expressed regret for not being more aware or paying more attention at that time,
They expressed regret for decisions previously made such as going for a mammogram in the first place.

I’ve got no regrets about my reaction I just wish that I hadn’t been to the screening in the first place. If I hadn’t gone for that wretched screening… ... I might have got three more really good years of life not worrying about anything. In fact, once I had been to the biopsy I lived with the fear of cancer coming (Participant 11).

A few participants did however consider mammography beneficial; for instance, Participant 8 commented that she considered her life to have been saved through a routine mammogram, but at the same time felt very strongly that she had managed to avoid overtreatment and make informed management choices.

All women mentioned some step of their diagnostic and treatment pathway where they felt that they did not provide informed consent; some said that they realised in hindsight that they may have been frightened into making some decisions that they were not ready to make. Some women believed that they had been denied crucial information to enable informed consent.

One of the things that so hurts is that…(they) gave me half the information. But they knew, they knew all about the controversy and the lack of information and they still wanted more than anything to process me, not to help me (Participant 11).

Throughout the interviews, the women’s reflections on their experiences highlighted the exhausting and lonely nature of the work involved to justify why they had chosen the choices and actions taken. Some said despite having had the recommended surgery, nothing had convinced them that they actually needed it in the first place. Several others reported that they felt confident they had made the right management decisions in choosing not to have a mastectomy, for example,

I think I made…absolutely the right decision… it was frightening, ‘cause when people…who did talk to me about DCIS talked about it, they talked about it as inevitable advancing to aggressive cancer…but I think we (my partner and I) made the best decision we could make. I think if I had gone along with the mastectomy and the reconstruction… I think I’d be very, very angry now… because I’m fine (Participant 1).

However, many said they will forever be wondering if they made the right decision—‘am I the needle in the haystack?’ (Participant 11), ‘have I done the right thing… would it have been better to… have a mastectomy and move on with life and not keep thinking about it?’ (Participant 4)—even after years spent ‘digesting’ (Participant 11) the possibility of overdiagnosis. Some described the trauma and anger that they had experienced over the years, I was beside myself with rage for several years and eventually that burns down and you just become sick of the whole thing, which now I am (Participant 11).

With the current state of knowledge, these women can never know if their decision was the right or best one, which is the nature of overdiagnosis.

And I’m sure that she thinks that I’m alive and well today because they caught it early. Whereas, I still don’t know that. I think I might be alive and well today with no further, repercussions at the moment at least, because I wasn’t really ill in the first place… I’m contributing to a misleading statistic and that I’ve reached the 5 year survival point, so everybody can cheer and that knocks that up to a success. But it’s not really a success if I was fine anyway and I was still going to be well at this point, and the NHS spent several thousand pounds curing me of something that could have been left well alone (Participant 5).

**Downstream effects on quality of life**

A number of the women were living with physical reminders of their experience, such as ‘really painful’ (Participant 4) pain in their breasts, disfigurement, scarring, exacerbated anxiety, lymphatic cording or the side effects of medications and early ‘super charged menopause’ (Participant 8) and the prolonged impacts of that on their quality of life. Some mentioned the stress and financial burden of bills and medical appointments, without knowing if the cancer needed to be found in the first place.

(mastectomy) affects things, affects my choices about what I wear and mastectomy bras are uncomfortable, and the whole experience has affected my travel insurance costs…it does have an impact, even after all this time… I had a bad time emotionally (Participant 5).

**Suggestions for other women**

All participants were asked, when reflecting on their personal experience, for advice on how to improve the experience for other women considering breast screening. Their suggestions are summarised in online supplemental file 3. Responses focused on individual level factors such as clinician responsibility to elicit and prioritise patient preferences, health system factors including creating opportunity for proper discussion about the benefits and harms of screening prior to attending a screening appointment, and society level factors like influencing a societal shift in thinking about and labelling cancer.

**DISCUSSION**

**Principal findings**

This unique international study documents the experience of a highly selected group of women diagnosed with DCIS or invasive breast cancer. These women have all
considered the possibility that they may have experienced breast cancer overdiagnosis. Some felt that they had experienced overtreatment and others had taken steps to avoid overtreatment. Our study shows how learning about overdiagnosis after a breast cancer diagnosis profoundly impacted these women’s sense of self, interactions with medical professionals, and for some, deep remorse about past decisions and actions. Many were uncomfortable with being treated as a cancer patient when they did not feel ‘diseased’ and being recommended treatments that seemed excessive in comparison to the diagnosis given. Some felt anger that critical information was not easily forthcoming and feeling they had not been given a complete picture of overdiagnosis before having screening mammography; and some were frustrated about how difficult it was to connect with medical professionals and others in their social network about overdiagnosis and overtreatment being a possibility. The findings highlight the loneliness of this experience, with little support or reassurance available to the women interviewed in this study. By describing the experience of women who independently self-identify as having a potentially overdiagnosed cancer, this study—which exemplifies the psychosocial harms of learning about overdiagnosis after a breast cancer diagnosis—makes an important contribution to the literature and to clinical practice. The sample also included several women who were more concerned by their recommended treatment which they perceived as overtreatment, rather than whether their cancer was ‘overdiagnosed’.

**Strengths and limitations**

A strength of this study was the use of qualitative interviews that allowed for (a) in-depth exploration of this unique experience of cancer at an individual patient level and (b) unanticipated findings to arise, with opportunity to explore such experiences in detail. The study recruited across four countries with established breast cancer screening programmes and involved a three-member consumer advisory panel with lived experience of breast cancer. This study is novel—other studies including our own have sought to explore how to inform women about overdiagnosis, whereas our aim was to hear and document the experience of individuals who wondered themselves whether they may have been overdiagnosed and/or overtreated, and possibly realised they are unlikely to ever know for sure as it is practically impossible to identify individuals who have been ‘overdiagnosed’. The diversity of our sample allowed us to illustrate a range of possibilities in terms of the impact of discovering overdiagnosis: (1) distress on finding out and questioning whether a diagnosis and treatment was potentially unnecessary; (2) being protected by this knowledge by taking steps to avoid overtreatment and (3) potentially damaging, if it encourages patients to decline treatment for potentially curable cancer. Another strength is that we verified women’s understanding of overdiagnosis and overtreatment as part of the study eligibility process by asking them what they understood by the terms. Their responses are reported in online supplemental file 1.

The number of participants is small and the study comprised of a highly selected and unusual sample. They were health literate and highly educated. This was inevitable, given our aim was to explore a specific experience, that of being aware of overdiagnosis and considering it in relation to one’s own experience of cancer diagnosis and treatment. Few women in the community are aware of and understand overdiagnosis and even those who do understand it are unlikely to have experienced it given that most screening mammograms are normal, reflecting that screening is an intervention for asymptomatic women. The experiences of the women documented in this study are therefore likely not shared by the majority of women in a similar position but are valid for those who identify with this experience. As this was a small sample, we cannot state that thematic saturation was achieved. Our study was conceived and led by researchers interested in improving understanding about overdiagnosis and to explore ways to deal with it. To minimise bias, the initial analysis was led and undertaken by a researcher with no previous involvement in breast cancer research. All the data reported were based on the women’s survey responses and/or their words during the interviews. It should be noted that diagnoses and treatments reported have not been verified, and they reflect the participants’ perceptions. While some treatments may have been perceived by them as overtreatment, our findings should not be taken to suggest that the treatment offered was incorrect or poor quality, as treatment recommendations may be made for many reasons not all of which may be apparent.

**Strengths and limitations in relation to other studies**

We know from a substantial body of epidemiological evidence that large numbers of women could be harmed by overdiagnosis at a population level, but this is the first study to our knowledge to document how women are personally impacted by the possibility that their screen-detected diagnosis may represent overdiagnosis and/or overtreatment. The women’s accounts show the significant negative psychosocial impact of awareness of overdiagnosis in the context of screen-detected breast cancer, particularly when not forewarned of the risk. The findings are relevant to all women who are considering or are participating in breast screening programmes, their clinicians and policymakers.

A previous study suggested that some women do not consider overdiagnosis information to be an issue for screening participation. However, this study shows the substantial negative impact of finding out about overdiagnosis after a diagnosis of breast cancer at least in some women. Randomised controlled trial data has shown that women can be safely informed about overdiagnosis before screening: educating women about overdiagnosis prior to screening improved understanding, reduced worry about breast cancer, and did not increase anxiety or reduce
willingness to participate in breast screening. This is consistent with other evidence showing that women value breast cancer screening and intend to participate in screening even when aware of the risk of overdiagnosis. A systematic review on women’s values and preferences around breast cancer screening showed that women are willing to tolerate the potential harms of screening for an early diagnosis, but highlighted concern that women may not understand the concept of overdiagnosis. Even in our highly educated, health literate sample of women, most (10/12) women found out about overdiagnosis after diagnosis (rather than before screening).

Research in the context of screening for cancer and in other settings has shown it is challenging to communicate about overdiagnosis. Overcoming this challenge will be essential however, as screening policy evolves in the light of emerging evidence and new risk assessment tools. A good understanding of the potential benefits and harms of screening will be key to successful implementation of these developments, including risk targeted screening with deintensification of screening for those at low risk.

**One theme identified was the difficulty of living with uncertainty about the possibility of overdiagnosis or overtreatment. It is not possible to identify whether any individual has been overdiagnosed or not, and as such it remains unknown whether the women in this study made the best decisions for their health or not. With time, it is likely that these issues will become salient to more women as the community becomes more familiar with the potential for overdiagnosis in breast cancer screening. Future biological research may be able to determine more accurately the prognosis of screen-detected breast cancer.**

Until then we recommend consideration be given to how to better inform women about the possibility of overdiagnosis before they undergo screening mammography to avoid the distress caused to women who are diagnosed and discover it later. Clinical and community support, for example provided by clinical nurse specialists, should also be available to the minority of women who identify with the possibility of having been overdiagnosed and possibly overtreated to cope with the uncertainty about their treatment choices and their prognosis as described by the women in this study.

The findings of this study could be tested in a larger representative sample; a randomised controlled trial could ascertain if there are women who suffer harm from undertreatment when informed about overdiagnosis. Future research could also repeat and improve this research in other jurisdictions and cultures with larger samples of women where breast cancer screening is offered. Investigating clinician-related barriers to effective communication may also be worthy of further investigation to inform communication training programmes. It is important to consider how best to inform people about the risk of overdiagnosis when establishing screening programmes. Such opportunities may exist in relation to lung cancer screening, which will likely be implemented in many countries following recent trials and recommendations. Additional implications for clinicians and policymakers are summarised in box 1.

### Box 1  Summary of implications for clinicians and policymakers (Derived from this study in addition to suggestions from previous research where indicated)

1. In the spirit of transparency, women should be given opportunity to be informed about the possibility of overdiagnosis and overtreatment prior to screening (and therefore diagnosis). Such an opportunity might avoid the negative psychosocial impact experienced by some of our study participants. An evidence-based information resource presented alongside breast screening invitations has been recommended by three European independent inquiries into breast cancer screening, yet has only been implemented at scale in the UK.
2. Consistent terminology and minimum standards to describe overdiagnosis and overtreatment as a potential downside of cancer screening should be prioritised in information resources. Information about overdiagnosis and overtreatment must be prominent during consent.
3. Better support, training and resources for clinicians to communicate about overdiagnosis and overtreatment during their consultations are warranted. Clinicians must be aware of their own preferences and how that influences the care and advice that they provide.
4. Specialists who consult women who have a screen-detected breast cancer should inform them of the risks and benefits of all management options available and be prepared to engage in evidence-based conversations about overdiagnosis and overtreatment. However, our study has shown that there were psychosocial harms, including anxiety, of the diagnosis itself, in addition to the harms of perceived overtreatment.
5. Strategies for reducing the harms of screen-detected DCIS have been suggested and may also have application in the context of mitigating the harms of overdiagnosis of screen-detected breast cancer, whichever DCIS or invasive.
6. Where appropriate, clinicians should consider participation in trials of active surveillance, de-escalated treatment of low-risk DCIS, newer less harmful treatments such as TARGIT-IORT and using lumpectomy for invasive breast cancer.

### CONCLUSION

These findings provide rare insight into the experience of a select group of women who found out about overdiagnosis after being given a diagnosis of breast cancer. While this cohort may represent a small proportion of all patients diagnosed with breast cancer, it is important that policymakers and clinicians improve current practice by considering these findings and suggestions made by our study participants. There is a need to adequately inform women considering breast screening of the risks of overdiagnosis and overtreatment.
Acknowledgements We are very grateful to our consumer advisors Elizabeth Dawson, Mitzi Blennerhassett and Donna Pinto whose courage and scientific questioning helped initiate and complete the study. They reviewed study materials, provided advice on participant recruitment, advertised the study on their blogs and reviewed the draft manuscript. We thank them for their participation and support without which the study would not have been possible. We also acknowledge the contribution of Hazel Thornton whose patient advocacy over many years has inspired us.

Contributors AB conceived the study. AB, BH, BM, KP were involved in designing the study and developing the methods. AB and KM obtained funding. AB and KP coordinated the running of the study. KP conducted the interviews. JSV reviewed the study materials and assisted with recruitment. KP and JH developed the analytical framework and performed the analysis. AB, KP, JH and JSV read transcripts and contributed to the interpretation. KP drafted the manuscript. All authors had significant intellectual contribution to the manuscript and critically revised the manuscript. KP, JH and AB are guarantors.

Funding Wiser Healthcare Australia. Wiser Healthcare is a research collaboration to reduce overdiagnosis and overtreatment, funded by the National Health and Medical Research Council of Australia Grant Numbers 1113532 and 1104136 www. wiserhealthcare.org.au.

Competing interests AB, KM, JH, BM, KP had financial support from the National Health & Medical Research Council, Australia for the submitted work. JSV reports a grant from the Health Technology Assessment Programme of National Institute of Health Research, UK during the conduct of the study. JSV received payment from Carl Zeiss for travel to meetings and honoraria outside the submitted work. AB is a member and Co-Chair of the Scientific Committee for the Preventing Overdiagnosis International Conferences. KP, BM and JH are members of the early career researcher committee for the Preventing Overdiagnosis International Conferences.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by The University of Sydney Human Research Ethics Committee (Project No. 2017/874). Participants gave informed consent to participate in the study before taking part. We worked with a three-person consumer advisory committee from the inception of the project.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Kristen Pickles http://orcid.org/0000-0002-1621-3217
Joly Hersh http://orcid.org/0000-0001-5225-6639
Brooke Nickel http://orcid.org/0000-0002-8100-4278
Jayant S Vaidya http://orcid.org/0000-0003-1760-1278
Kristen McCaffery http://orcid.org/0000-0003-2696-5006

REFERENCES

1 Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605–13.

2 Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms of breast cancer screening: an independent review. Br J Cancer 2013:108:2205–40.

3 Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015;350:g7773.

4 Glaziou PP, Jones MA, Pathirana T, et al. Estimating the magnitude of cancer overdiagnosis in Australia. Med J Aust 2020;212:163–8.

5 Bewley S, Blennerhassett M, Payne M. Cost of extending the NHS breast screening age range in England. BMJ 2019;365:j1293.

6 Hersch J, Jansen J, McCaffery K. Decision-Making about mammographic screening: pursuing informed choice. Climacteric 2018;21:209–13.

7 Zapka JG, Geller BM, Bulliard J-L, et al. Print information to inform decisions about mammography screening participation in 19 countries with population-based programs. Patient Educ Couns 2006:63:126–37.

8 Jørgensen KJ, Gotzsche PC. Content of invitations for publicly funded screening mammography. BMJ 2006;332:538–41.

9 Moynihan R, Nickel B, Hersch J, et al. What do you think overdiagnosis means? A qualitative analysis of responses from a national community survey of Australians. BMJ Open 2015;5:e007436.

10 Henniksen MJV, Guassora AD, Brodersen J. Preconceptions influence women’s perceptions of information on breast cancer screening: a qualitative study. BMC Res Notes 2015;8:404.

11 Hersch J, Jansen J, Barratt A, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ 2013;346:f1518.

12 Davies L, Hendrickson CD, Hanson GS. Experience of US patients who self-identify as having an overdiagnosed thyroid cancer: a qualitative analysis. JAMA Otolaryngol Head Neck Surg 2017;143:663–9.

13 McCaffery K, Nickel B, Pickles K, et al. Resisting recommended treatment for prostate cancer: a qualitative analysis of the lived experience of possible prostate overdiagnosis. BMJ Open 2019;9:e029960.

14 Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. sage, 2006.

15 Wailer J, Douglas E, Whitaker KL, et al. Women’s responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. BMJ Qual Health Res 2015;3:e002703.

16 Hersch J, Barratt A, Jansen J, et al. Use of a decision aid including information on overdiagnosis to support informed choice about breast cancer screening: a randomised controlled trial. Lancet 2015;385:1642–52.

17 Seaman K, Dzidek PL, Castell E, et al. A systematic review of women’s knowledge of screening mammography. Breast 2018;42:81–93.

18 Hersch J, Barratt A, McGeechan K, et al. Informing women about Overdiagnosis in breast cancer screening: two-year outcomes from a randomized trial. J Natl Cancer Inst 2021;113:1523–30.

19 Stiggelbout A, Copp T, Jacklyn G, et al. Women’s acceptance of Overdiagnosis in breast cancer screening: can we assess harm-benefit tradeoffs? Med Decis Making 2020;40:42–51.

20 Mathioudakis AG, Salakari M, Pylkkanen L, et al. Systematic review on women’s values and preferences concerning breast cancer screening and diagnostic services. Psychooncology 2019;28:939–47.

21 McCaffery KJ, Jansen J, Scherer LD, et al. Walking the tightrope: communicating overdiagnosis in modern healthcare. BMJ 2016;352:j348.

22 Rozbroj T, Haas R, O’Connor D, et al. How do people understand overtaking and overdiagnosis? systematic review and meta- synthesis of qualitative research. Soc Sci Med 2021;285:114255.

23 Esserman LJ, Esserman LJ. The wisdom study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 2017;3:1–7.

24 Pashayan N, Morris S, Gilbert FJ, et al. Cost-Effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol 2018;4:1504–10.

25 Esserman LJ, Yao C, Thompson CK, et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol 2017;3:1503–10.

26 Esserman LJ, Yao C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 2015;1:881–3.

27 US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for lung cancer: US preventive services Task force recommendation statement. JAMA 2021;325:962–70.

28 Canadian Task Force on Preventive Health Care. Recommendations on screening for lung cancer. CMAJ 2019;191:E75–32.

29 Cancer Australia. Report on the lung cancer screening enquiry. cancer. Australia, Surry Hills, NSW: Cancer Australia, 2020.
30 British Lung Foundation. A national five year plan for lung health. Taskforce for lung health, 2018.
31 Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss medical board. N Engl J Med 2014;370:1965–7.
32 Barratt A, Jørgensen KJ, Autier P. Reform of the National screening mammography program in France. JAMA Intern Med 2018;178:177–8.
33 Houston AJ, Lowenstein LM, Hoffman A, et al. A review of the presentation of overdiagnosis in cancer screening patient decision AIDS. MDM Policy Pract 2019;4:238146831988144.
34 Council GM. Good medical practice report, 2020.
35 French DP, Astley S, Brentnall AR, et al. What are the benefits and harms of risk stratified screening as part of the NHS breast screening programme? study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). BMC Cancer 2020;20:1–14.
36 Vaidya JS, Bulsara M, Baum M, et al. New clinical and biological insights from the International TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. Br J Cancer 2021;125:380–9.
37 Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ 2020;370:m2836.
38 Marmot M, Altman G, et al, Independent UK Panel on Breast Cancer Screening. Independent UK panel on breast cancer screening replies to Michael Baum. BMJ 2013;346:f873.